For example, bryostatin has been shown to increase CD22 on tumor cells and has demonstrated safety in clinical trials and could therefore be given prior to CAR for patients with low CD22 expression to try to improve CAR efficacy [43, 44]. The gene discussed is CD22; the disease is neoplasm.